Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Change in Accured Expenses (2020 - 2025)

Oncology Institute (TOI) has disclosed Change in Accured Expenses for 6 consecutive years, with $127000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 95.53% year-over-year to $127000.0, compared with a TTM value of $7.0 million through Sep 2025, down 7.22%, and an annual FY2024 reading of $9.5 million, up 182.13% over the prior year.
  • Change in Accured Expenses was $127000.0 for Q3 2025 at Oncology Institute, up from -$305000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.4 million in Q1 2024 and bottomed at -$4.5 million in Q4 2021.
  • Average Change in Accured Expenses over 5 years is $762210.5, with a median of $358000.0 recorded in 2021.
  • The sharpest move saw Change in Accured Expenses skyrocketed 23966.67% in 2021, then crashed 332.23% in 2023.
  • Year by year, Change in Accured Expenses stood at -$4.5 million in 2021, then skyrocketed by 87.93% to -$545000.0 in 2022, then surged by 609.72% to $2.8 million in 2023, then surged by 67.6% to $4.7 million in 2024, then plummeted by 97.27% to $127000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for TOI at $127000.0 in Q3 2025, -$305000.0 in Q2 2025, and $2.6 million in Q1 2025.